Prevnar 13 Post-Market Trials Must Confirm Surrogate Endpoint, Deal With Immunogenicity
Executive Summary
New post-marketing commitment will look at conjugate pneumonia vaccine when given in patients 50 and older who have already received Merck’s polysaccharide vaccine.
You may also be interested in...
Vaccine Biomarkers: Don't Put Cart Before Horse When Designing Studies, US FDA Advises
If a sponsor wants to use a biomarker to show vaccine effectiveness, it should first explain why a clinical endpoint study is not feasible, US FDA official advises.
Prevnar 13 Loses ‘Routine’ Endorsement For Older Adults In CDC Panel Vote
ACIP still supports use of Pfizer’s pneumococcal vaccine in immunocompetent individuals ages 65 years and older based on shared clinical decision-making, but concludes that routine immunization is no longer warranted due to herd effect from pediatric vaccination.
Prevnar 13 Recommendation For Medicare Population May Be Short Lived
CDC advisory committee support for Pfizer pneumococcal vaccine in adults 65 and older comes with caveat that recommendation will be re-examined, and possibly revised, in 2018 due to effects of herd immunity.